Joseph E. Gilliam, President and COO of Glaukos Corp (NYSE: ), recently executed a series of transactions involving the company’s common stock. The transactions come as the stock trades near a 52-week high of $151.92, which has delivered an impressive 86% return year-to-date. On December 20, Gilliam sold a total of 3,328 shares, generating a profit of $498,715. The sale was made at prices ranging from $149.54 to $150.35 per share.

In addition to these sales, Gilliam also exercised stock options to acquire 3,328 shares of Glaukos common stock. These options were exercised at prices of $39.10 and $69.30 per share, for a total transaction value of $198,829. The $8.2 billion market cap company maintains strong financial health with a current ratio of 5.54, indicating sufficient liquidity to meet short-term obligations.

The transactions were made under a Rule 10b5-1 trading plan, which allows insiders of publicly traded corporations to set up a predetermined plan to sell the company’s stock, which helps avoid of concerns about insider trading. Following these transactions, Gilliam owned 102,169 shares of Glaukos stock. According to InvestingPro analysis, analyst price targets for Glaukos range from $115 to $162, with 12 additional key insights available to subscribers through the comprehensive Pro Research Report.

In other recent news, Glaukos Corporation has submitted a New Drug Application (NDA) to the FDA for Epioxa, a non-invasive treatment for keratoconus. This development marks an important step for Glaukos in its efforts to offer a less invasive treatment option for patients with this progressive eye disease. The submission includes positive data from two Phase 3 pivotal trials. If approved, Epioxa will be the first FDA-sanctioned, non-invasive corneal cross-linking therapy that preserves the corneal epithelium.

In financial news, Glaukos received approximately $53.2 million from the unwinding of a portion of closed call transactions, originally entered into in connection with the issuance of 2.75% Convertible Senior Notes due 2027. In addition, the company’s iDose revenue will double in the third quarter of 2024, reaching approximately $8 million, with coverage expected which will increase significantly by 2025.

Analysts have given different views for Glaukos. Citi upgraded Glaukos from Neutral to Buy, expecting a positive turnaround in sales of its iDose product in 2025. Mizuho (NYSE:) Securities maintained a Neutral rating on Glaukos but raised the price target in anticipation of a significant year ahead for the company. These are the latest developments in the continued growth and potential of Glaukos Corporation.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.